3 days ago · Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves a gradual loss of kidney function.

1 day ago · The US Food and Drug Administration (FDA) approved semaglutide (Ozempic, Novo Nordisk) for reducing the risk for worsening kidney disease and cardiovascular death in adults …

3 days ago · Type 2 diabetes is a leading cause of chronic kidney disease, which affects more than one in seven U.S. adults. The medication can lower the chance that patients with both …

2 days ago · Novo Nordisk is conducting a different study to understand how and why semgalutide seems to reduce the progression of kidney disease, said Stephen Gough, global …

2 days ago · PLAINSBORO, N.J., Jan. 28, 2025 /PRNewswire/ -- Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved Ozempic ® to reduce the risk …

2 days ago · The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients …

2 days ago · Novo Nordisk estimates that around 40% of people with type 2 diabetes have chronic kidney disease, which affects about 37 million adults in the United States. MORE: Places the …

Stay up to date with Novo Nordisk’s latest research, scientific publications, congress materials and other medical resources on chronic kidney disease (CKD).

May 24, 2024 · Semaglutide reduced the risk of clinically important kidney outcomes and death from cardiovascular causes in patients with type 2 diabetes and chronic kidney disease. …

Aug 30, 2024 · In March 2024, Novo announced positive results from the kidney outcomes trial FLOW. According to the trial, semaglutide 1.0mg reduced risk of kidney disease progression …